To investigate the positivity rate of TTV, a novel transfusion-transmitted
virus, in serum of patients with chronic liver diseases as well as the effi
cacy of interferon treatment, serum samples of 183 cases with chronic liver
diseases and 111 healthy controls were examined by nested PCR and all PCR
products were sequenced. In total 11.5% (21/183) of serum was positive for
TTV DNA, including nine (8.5%) of 106 patients with chronic hepatitis C, tw
o (14.3%) of 14 with non A, B, C liver disease, three (20%) of 15 with cirr
hosis, four (20%) of 20 patients with hepatocellular carcinoma, one (14.3%)
of seven patients with alcoholic liver disease, one (7.7%) of 13 with prim
ary biliary cirrhosis, one (12.5%) of eight patients with autoimmune hepati
tis and five (4.5%) of 111 healthy controls. A total of 11 patients had poi
nt mutations in the nucleotide region between 2061 and 2257 from N-terminal
end. A total of five patients positive for TTV DNA were examined before an
d after interferon treatment. Four patients had no detectable TTV DNA after
interferon treatment, but one patient was still positive. These findings s
uggest that TTV infection is not correlated with a specific chronic liver d
isease. Although the sample size was very small, TTV appeared to be sensiti
ve to interferon therapy. (C) 1999 Elsevier Science Ireland Ltd. All rights
reserved.